Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
JAMES MULAY	Director	2026-07-10	20K shares	$1.48M
JAMES MULAY	Director	2026-07-01	4K shares	$279K
POST LEONARD E	Director	2026-06-24	5K shares	$329K
POST LEONARD E	Director	2026-06-22	6K shares	$366K
POST LEONARD E	Director	2026-06-04	3K shares	$163K

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding CG ONCOLOGY INC (CGON)?

Major stakeholders currently include Rtw Investments, LP ($472.7M), T. Rowe Price Investment Management, Inc. ($454.8M), Decheng Capital LLC ($431.2M). Based on the latest 13F filings, there are a total of 238 tracked investment funds and institutions maintaining positions in CGON.

What is the overall institutional sentiment toward CGON recently?

Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $2.7B, driven by 141 managers accumulating shares while 87 reduced their exposure.

Which institutions have been selling or reducing their CGON positions?

In the latest period, 65 funds trimmed their holdings, and 22 managers completely exited their positions. The aggregate reported sell value was $1.8B.

Are there any notable investors adding CGON to their portfolios?

Yes, buying activity remains notable. 59 institutions opened new positions in {ticker}, and 82 existing holders added to their shares. The total reported buy value for the quarter amounted to $2.8B.